Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance

被引:41
|
作者
Zheng, Ningbo [1 ]
Fang, Jing [1 ]
Xue, Gang [1 ]
Wang, Ziyu [1 ]
Li, Xiaoyin [2 ]
Zhou, Mengshi [2 ]
Jin, Guangxu [1 ]
Rahman, Masmudur M. [3 ]
McFadden, Grant [3 ]
Lu, Yong [1 ]
机构
[1] Wake Forest Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27101 USA
[2] St Cloud State Univ, Dept Math & Stat, St Cloud, MN 56301 USA
[3] Arizona State Univ, Biodesign Ctr Immunotherapy Vaccines & Virothera, Tempe, AZ 85287 USA
关键词
ONCOLYTIC VIRUS; DEATH; AUTOPHAGY; MODELS; THERAPY; PROTEIN; AKT;
D O I
10.1016/j.ccell.2022.08.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cytotoxicity of tumor-specific T cells requires tumor cell-to-T cell contact-dependent induction of classic tumor cell apoptosis and pyroptosis. However, this may not trigger sufficient primary responses of solid tumors to adoptive cell therapy or prevent tumor antigen escape-mediated acquired resistance. Here we test myxoma virus (MYXV)-infected tumor-specific T (T-MYXV) cells expressing chimeric antigen receptor (CAR) or T cell receptor (TCR), which systemically deliver MYXV into solid tumors to overcome primary resistance. In addition to T cell-induced apoptosis and pyroptosis, tumor eradication by CAR/TCR-T-MYXV cells is also attributed to tumor cell autosis induction, a special type of cell death. Mechanistically, T cell-derived interferon gamma (IFN gamma)-protein kinase B (AKT) signaling synergizes with MYXV-induced M-T5-SKP-1-VPS34 signaling to trigger robust tumor cell autosis. CAR/TCR-T-MYXV-elicited autosis functions as a type of potent bystander killing to restrain antigen escape. We uncover an unexpected synergy between T cells and MYXV to bolster solid tumor cell autosis that reinforces tumor clearance.
引用
收藏
页码:973 / +
页数:20
相关论文
共 50 条
  • [21] Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy
    Dreyzin, Alexandra
    Rankin, Alexander W.
    Luciani, Katia
    Gavrilova, Tatyana
    Shah, Nirali N.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2024, 20 (07) : 745 - 763
  • [22] Defined Tumor Antigen-Specific T Cells Potentiate Personalized TCR-T Cell Therapy Targeting Neoantigens
    Zhou, Penghui
    He, Jingjing
    Xiong, Xinxin
    Yang, Han
    Li, Dandan
    Liu, Xuefei
    Liu, Haiping
    Ding, Peirong
    Zhang, Xiaoshi
    Liu, Zhenjiang
    Li, Wende
    Zuo, Zhixiang
    CANCER SCIENCE, 2022, 113 : 647 - 647
  • [23] Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope
    Liu, X. F.
    Onda, M.
    Schlomer, J.
    Bassel, L.
    Kozlov, S.
    Tai, C. -H.
    Zhou, Q.
    Liu, W.
    Tsao, H. -E.
    Hassan, R.
    Ho, M.
    Pastan, I.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2024, 121 (04)
  • [24] IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
    Adachi, Keishi
    Kano, Yosuke
    Nagai, Tomohiko
    Okuyama, Namiko
    Sakoda, Yukimi
    Tamada, Koji
    NATURE BIOTECHNOLOGY, 2018, 36 (04) : 346 - +
  • [25] IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
    Keishi Adachi
    Yosuke Kano
    Tomohiko Nagai
    Namiko Okuyama
    Yukimi Sakoda
    Koji Tamada
    Nature Biotechnology, 2018, 36 : 346 - 351
  • [26] How can Cytokine-induced killer cells overcome CAR-T cell limits
    Cappuzzello, Elisa
    Vigolo, Emilia
    D'Accardio, Giulia
    Astori, Giuseppe
    Rosato, Antonio
    Sommaggio, Roberta
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [27] Exploring BiTE-Integrated CAR T-Cell Therapy to Overcome Tumor Antigen Escape and Reinforce CAR-T Therapy in Mantle Cell Lymphoma
    Crutchfield, Grace Glass
    Liu, Yang
    Yan, Fangfang
    Li, Xiaolin
    Lee, Heng-Huan
    Wang, Michael
    Yao, Yixin
    BLOOD, 2023, 142
  • [28] Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response
    Jingjing He
    Xinxin Xiong
    Han Yang
    Dandan Li
    Xuefei Liu
    Shuo Li
    Shuangye Liao
    Siyu Chen
    Xizhi Wen
    Kuai Yu
    Lingyi Fu
    Xingjun Dong
    Kaiyu Zhu
    Xiaojun Xia
    Tiebang Kang
    Chaochao Bian
    Xiang Li
    Haiping Liu
    Peirong Ding
    Xiaoshi Zhang
    Zhenjiang Liu
    Wende Li
    Zhixiang Zuo
    Penghui Zhou
    Cell Research, 2022, 32 : 530 - 542
  • [29] Lenalidomide Enhances CAR-T Cell Activity Against Solid Tumor Cells
    Wang, Zhixiong
    Zhou, Guomin
    Risu, Na
    Fu, Jiayu
    Zou, Yan
    Tang, Jiaxing
    Li, Long
    Liu, Hui
    Liu, Qian
    Zhu, Xuekai
    CELL TRANSPLANTATION, 2020, 29
  • [30] Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response
    He, Jingjing
    Xiong, Xinxin
    Yang, Han
    Li, Dandan
    Liu, Xuefei
    Li, Shuo
    Liao, Shuangye
    Chen, Siyu
    Wen, Xizhi
    Yu, Kuai
    Fu, Lingyi
    Dong, Xingjun
    Zhu, Kaiyu
    Xia, Xiaojun
    Kang, Tiebang
    Bian, Chaochao
    Li, Xiang
    Liu, Haiping
    Ding, Peirong
    Zhang, Xiaoshi
    Liu, Zhenjiang
    Li, Wende
    Zuo, Zhixiang
    Zhou, Penghui
    CELL RESEARCH, 2022, 32 (06) : 530 - 542